Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free CMRAW Stock Alerts

Comera Life Sciences (CMRAW) Competitors

Compare

CMRAW vs. SXTPW, BFRIW, CALA, CINGW, and CDTTW

Should you buy Comera Life Sciences stock or one of its competitors? Comera Life Sciences's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Calithera Biosciences (CALA), Cingulate (CINGW), and Conduit Pharmaceuticals (CDTTW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Comera Life Sciences compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Comera Life Sciences (NASDAQ:CMRAW) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Comera Life Sciences. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Comera Life Sciences. 60 Degrees Pharmaceuticals' average media sentiment score of 1.87 beat Comera Life Sciences' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Comera Life Sciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Summary

60 Degrees Pharmaceuticals beats Comera Life Sciences on 3 of the 3 factors compared between the two stocks.

How does Comera Life Sciences compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Comera Life Sciences (NASDAQ:CMRAW) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Comera Life Sciences N/A N/A N/A

In the previous week, Biofrontera had 3 more articles in the media than Comera Life Sciences. MarketBeat recorded 3 mentions for Biofrontera and 0 mentions for Comera Life Sciences. Biofrontera's average media sentiment score of 0.96 beat Comera Life Sciences' score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Positive
Comera Life Sciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

Summary

Biofrontera beats Comera Life Sciences on 3 of the 3 factors compared between the two stocks.

How does Comera Life Sciences compare to Calithera Biosciences?

Comera Life Sciences (NASDAQ:CMRAW) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Calithera Biosciences N/A N/A N/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Calithera Biosciences Neutral

Comera Life Sciences has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00MN/AN/AN/AN/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Summary

Comera Life Sciences beats Calithera Biosciences on 1 of the 1 factors compared between the two stocks.

How does Comera Life Sciences compare to Cingulate?

Comera Life Sciences (NASDAQ:CMRAW) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00MN/AN/AN/AN/A
CingulateN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Cingulate N/A N/A N/A

In the previous week, Cingulate had 2 more articles in the media than Comera Life Sciences. MarketBeat recorded 2 mentions for Cingulate and 0 mentions for Comera Life Sciences. Cingulate's average media sentiment score of 1.44 beat Comera Life Sciences' score of 0.00 indicating that Cingulate is being referred to more favorably in the news media.

Company Overall Sentiment
Comera Life Sciences Neutral
Cingulate Positive

Summary

Cingulate beats Comera Life Sciences on 2 of the 3 factors compared between the two stocks.

How does Comera Life Sciences compare to Conduit Pharmaceuticals?

Conduit Pharmaceuticals (NASDAQ:CDTTW) and Comera Life Sciences (NASDAQ:CMRAW) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

In the previous week, Conduit Pharmaceuticals had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Conduit Pharmaceuticals and 0 mentions for Comera Life Sciences. Conduit Pharmaceuticals' average media sentiment score of 1.87 beat Comera Life Sciences' score of 0.00 indicating that Conduit Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Conduit Pharmaceuticals Very Positive
Comera Life Sciences Neutral

Company Net Margins Return on Equity Return on Assets
Conduit PharmaceuticalsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conduit PharmaceuticalsN/AN/AN/AN/AN/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

Summary

Conduit Pharmaceuticals beats Comera Life Sciences on 2 of the 3 factors compared between the two stocks.

Get Comera Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMRAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMRAW vs. The Competition

Export
MetricComera Life SciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$11.89B$7.06B$13.10B
Dividend YieldN/A2.70%2.57%10.45%
P/E RatioN/A775.15269.0625.28
Price / SalesN/A743.86602.4391.76
Price / CashN/A66.4570.4850.90
Price / BookN/A11.6012.916.24
Net IncomeN/A$2.77B$3.45B$347.60M

Comera Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMRAW
Comera Life Sciences
N/AN/AN/AN/A$0.00$1.00MN/A2
SXTPW
60 Degrees Pharmaceuticals
N/A$0.03
flat		N/A-67.6%$0.00$1.00MN/A2
BFRIW
Biofrontera
N/A$0.02
-22.4%		N/A-81.6%$0.00$43.20MN/A70
CALA
Calithera Biosciences
N/AN/AN/AN/A$0.00N/AN/A60
CINGW
Cingulate
N/A$0.01
-22.6%		N/A-87.9%$0.00N/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMRAW) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
The Shocking Discovery Investigators Found Hidden Inside America's Port Cranes
U.S. investigators found unexplained cellular modems inside cranes made by a Chinese state-owned company that ...
Altimetry | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel
$100 for this… $500 for that. Here’s how to stop the bleeding today
Rising costs are squeezing households nationwide. USA Today reports more families are moving in together, whil...
Brownstone Research | Sponsoredtc pixel